Assessing the link between gut microbiome and neurodegenerative diseases to explore the potential of this critical field

During the 8th Microbiome Movement – Drug Development Summit, held in London at the end of January, MicrobiomePost discussed with Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, about how the research in gut-brain axes could pave the way to new microbiome based therapies in multiple sclerosis and other neurodegenerative diseases.